HIVEP2

Across TCGA pan-cancer cohorts, HIVEP2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HIVEP2 data layer compared with 30 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HIVEP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HIVEP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where HIVEP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.072	0.978	.024	5	view →
LUAD	DFS	Median	All	0.501	0.846	.032	2	view →
PDAC	DFS	Median	All	0.679	0.399	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HIVEP2–CCRCC (DFS)

Open the CCRCC breakdown →